Terumo Corporation · TSE:4543
Terumo — Investor Presentation (December 2021)
18 slides from Terumo's investor presentation, Dec 16, 2021
Slide 1: Celebrating our 100th founding anniversary: 5-Year Growth Strategy with a 10-Year Vision
Celebrating our 100th founding anniversary: 5-Year Growth Strategy with a 10-Year Vision 05 | Corporate Fumihisa Hirose, General Manager, Strategic Planning Dept. and CTO ©TERUMO CORPORATION 1 / 17
Slide 2: Safe Harbor for Forward-Looking Statements and Use of Document
Safe Harbor for Forward-Looking Statements and Use of Document Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future even
Slide 3: 5-Year Growth Strategy with a 10-Year Vision
Celebrating our 100th founding anniversary: 5-Year Growth Strategy with a 10-Year Vision FY32~ FY27~31 Lead paradigm shift in medical care and make a leap toward Strengthen corporate foundation a “New Terumo” GS26 FY22~26 and generate solid profit from high- Strengthen existing businesses and growth
Slide 4: Vision for the Next Years: From Devices to Solutions
Vision for the Next 10 Years From Devices To Solutions Focus in solutions: The 3Ds 01 02 03 TM Delivery Digital Deviceuticals High value-added biological Disease-based approach Maximize drug effectiveness through access and delivery for advanced focused on improving long-term innovative devices medi
Slide 5: Delivery
01 Pursue vascular Pioneer new treatment routes Delivery delivery Deliver treatment to areas and cases that were previously including nonvascular routes Develop new treatments through completely different routes High value-added biological access difficult to reach and delivery for advanced medical
Slide 6: Digital
Connect before and Connect inside and outside 02 after surgery to provide the hospital to prevent serious Digital optimal treatment Connect advanced medical data to recommend treatments that suit the diseases Connect the acute and chronic phases to detect recurrence and onset of disease and prevent
Slide 7: Devi-ceuticals
03 Devi- TM Drug & Device combination for optimal dosing Manage dosage and timing with data obtained from patients ceuticals Maximize drug effectiveness through innovative devices Ratio of combination products (pharmaceutical + device) 30% or less • Accelerate the evolution of combination Achieve ef
Slide 8: Innovation Will Drive Future Growth
Innovation Will Drive Future Growth FY22~26 (GS26) FY27~ Hybrid Intradermal Venous Solution Robotic Delivery to stent graft administration surgical epicardium 01 device support and brain Delivery Strengths of companies Digital therapy Cell-related data Clinical Decision- In-home Hospital support col
Slide 9: Drive Projects through Technology CoE and Differentiation through Technological Capabilities
Drive Projects through Technology CoE and Differentiation through Technological Capabilities Technology CoE（Center of Excellence） Focus Areas Mechanical Material Bio Digital Evaluation Design / Pharmaceutical Sensing of Innovation Processing Technology /Regenerative Medicine 01 Cardiovascular relate
Slide 10: Terumo Aims toward Digital Transformation in Healthcare
Terumo Aims toward Digital Transformation in Healthcare Support treatment decision making Personalize minimally invasive therapies based on patient data Digitalize disease management Provide data management, drug delivery systems and digital therapies to the wide range of diseases that Terumo addres
Slide 11: Creating New Medical Value by Combining Terumo Strengths with Advanced Technologies Partners
Creating New Medical Value by Combining Terumo Strengths with Advanced Technologies Partners AI-based image and predictive analytics Broad business domain and customer contact Remote monitoring with wearable devices Medical device manufacturing technologies and capabilities Robust cloud infrastructu
Slide 12: Maximize the Potential of Human Resources
Maximize the Potential of Human Resources Achieve Transformation Realize Global Management Acquire new skills of Develop global leaders and strategic importance human resources X 2.5 X 10 Acquire digital human resource (5-Year target) Human capital pool of global leaders Growth Mindset Diversify hum
Slide 13: Value Creation through Collaboration (VC2) Program
Achieve 2% pts Profitability Improvement through Group-wide “Value Creation through Collaboration (VC2)” Program Group-wide profit improvement (SG&A) Group-wide profit 20~% improvement +1.0% Effect of non-recurring (Production) expenses (EU-MDR, etc.) +0.7% +1.0% Business and product mix improvement
Slide 14: Optimize Global Production
Optimize Global Production Strengthen global production Promote production innovation network - Strategically leverage low-cost production locations for - Drive automation, lean production, and digitalization efficient and stable supply to major markets - Leverage the core competencies of quality an
Slide 15: Achieve Group-wide Optimization through Focus Areas
Achieve Group-wide Optimization through 4 Focus Areas Global team ◼ 2% pts profit improvement Support Production Procurement Logistics functions ◼ Group-wide optimization ◼ Targeting high- ⚫ Production ⚫ Optimum ⚫ Enhance S&OP ⚫ Standardize and impact functions network sourcing across to right-size
Slide 16: ESG
ESG E Achieving carbon neutrality CO2 emissions (compared to FY18) Reduce 50% | FY30 Set in accordance with SASB, etc. Reduce 100% | FY40 Renewable Energy Use Usage rate 50% | FY30 CO2 emissions (vs. FY18, scope 1/2) Effective use of resources Water consumption (compared to FY18) Reduction rate 20%
Slide 17: CSV
CSV Promote medical technologies and services and improve access to healthcare Ratio of Radial procedure (FY26) TRI ≥70%, R2P ≥20%, RAVI ≥20%, Neuro ■ Further adoption of the radial procedure 10% ■ Provide solutions to problems in medical settings Medical safety・streamlining hospital management (num
Slide 18: ~“TERUMO
~“TERUMO